Avalo Therapeutics, Inc. Appoints Keith Maher to the Board
October 18, 2021 at 04:12 pm EDT
Share
The board of directors of Avalo Therapeutics, Inc. appointed Keith Maher, MD, to the Board, effective immediately, pursuant to the right of Armistice Capital Master Fund Ltd. (?Armistice?) to appoint two directors to the Board. Dr. Maher will serve as a director until the Company?s 2022 Annual Meeting of Stockholders or until his successor is duly elected and qualified.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (AVTX-002) (anti-LIGHT monoclonal antibody (mAb)) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Quisovalimab shows reduction of Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT) levels, as well as a favorable safety and tolerability profile, in all indications studied including COVID-19 acute respiratory distress syndrome (ARDS), Crohn's Disease, and non-eosinophilic asthma (NEA).
AVALO THERAPEUTICS, INC. 
